A triple negative breast cancer: what it is not!

Suresh B Katakkar
Regional Medical Oncology
Hematology Leader, Centre for the North, BC Cancer Agency, Prince George, British Columbia, Canada

Abstract: The triple negative cancer is an unusual, and at the same time, a unique entity where the discordance rate is almost 18%. That means 18% of Her2 negative results will transform into a Her2 positive status and will have the affinity to spread to the central nervous system (CNS). With the identification of CD44, CD24, and ALDH1, we may be able to determine which group of triple negative breast cancer patients will have CNS metastasis. This case illustrates the Her2 expressing cells have higher CNS affinity. As the original tumor was Her2 negative, if a genomic assay was then done on this patient, we would have identified the potential of CNS involvement. In conclusion, genomic assays should be routinely done on triple negative cancers.

Keywords: triple negative, breast cancer, claudin high or low, genomic microassay

Introduction
With this case illustration, we want to show how a triple negative breast cancer is not what it appears to be. The triple negative breast cancer is a unique entity that has been shown to be basal. This is definitely not one disease; genomic and microarray assays have shown this to be inhomogeneous cancer. Though we could not perform the genomic assay, had it been done we believe we could have shown in this patient CD44 high, CD24 low, and ALDH1 high expressing cells.

Case history
Our patient was in triple negative stage II and treated with anthracycline- and taxane-based chemotherapy, but when it metastasized, it showed Her2 positive cancer cells in the CNS location and triple negative features in the lung metastasis. This is the first reported human case that such discordance between primary and metastatic disease is shown.

A 43-year-old female patient was diagnosed with infiltrating ductal carcinoma of the left breast. She underwent a left modified radical mastectomy at Mayo Clinic in Scottsdale, AZ. Her carcinoma was triple negative and was 1.5 centimeters in size with two axillary lymph nodes showing metastasis. She then had adjuvant chemotherapy with epirubicin and docetaxel 75 mg/m² intravenously, every 3 weeks for six sessions. She required granulocyte colony-stimulating factor support from the second session onwards, as she developed febrile neutropenia following the first chemotherapy treatment.

Two years later, whilst in remission, she had a bilateral reconstruction following simple mastectomy on the right side. In the third year, as she was visiting her family in Puerto Rico, she developed severe headaches followed by seizures. The computed tomography (CT)
scan showed singular CNS metastasis. After stabilization, she was transferred to Tucson, Arizona, to the author’s care. There, a magnetic resonance imaging (MRI) of the head confirmed singular metastasis in the left frontal lobe. The patient had no localizing signs. The CT scan of the abdomen, chest, and pelvis showed right hilar metastasis. The central nervous system (CNS) metastasis was completely resected and showed Her2 positive and hormone receptor negative cancer. She received CNS radiation and FILM chemotherapy along with trastuzumab. After three sessions, she had a repeated MRI of the head and a CT scan of the chest, abdomen, and pelvis. She was in complete remission. She received three additional sessions of chemotherapy and continued trastuzumab for 1 year.

Three months later, she had an MRI of the head which showed she had no recurrence; however, a positron emission tomography (PET) CT scan showed recurrence of a right hilar mass, but no evidence of any other metastasis. She was then started on capecitabine and trastuzumab. After 3 months, a repeat PET CT scan showed partial response and an MRI of the head was still negative for recurrence. She had good performance status, therefore a mini thoracotomy was done and the right hilar mass was completely removed. To our surprise, this mass was triple negative like the primary. She then received three additional sessions of capecitabine and trastuzumab was withheld.

Four months later, she had right upper quadrant pain and a PET CT scan showed liver metastasis and recurrence of a right hilar mass. At this stage, her performance status was poor; hence, she was introduced to hospice services. She passed away three weeks later.

Discussion

This case illustrates the inhomogeneous feature of triple negative breast cancers and the difficulty in treating them. With the advent of new research in genomic and microarray assay, we believe that we can identify groups of patients with a higher potential of CNS metastasis.

It is well known that triple negative breast cancers have poor prognoses. Almost one third of them have CNS metastasis. The triple negative breast cancers are basal and recent genomic and microarray studies have shown it to be very heterogeneous. Prat and Perou have shown it to be claudin high or low. In addition, further genomic analysis has shown that some of the basal types are CD44 high, CD24 low, and ALDH1 high, whereas some are CD44 low, CD24 high, and ALDH1 low. It is the former type that has shown to have a predisposition for CNS involvement. The discordance rate in triple negative breast cancers has been shown to be 17.6%. That means 17.6% of triple negative breast cancers transform to Her2 positive status. Brufsky et al have shown that almost 33% of Her2 positive breast cancers have had CNS metastasis.

Triple negative breast cancers have also shown increased vascularity on MRI scans of the breast, indicating increased angiogenesis. Does this mean they secrete an increased amount of vascular endothelial growth factor and, if so, should we incorporate angiogenesis inhibitor routinely with chemotherapy in these patients?

Even though the Food and Drug Administration has retracted approval of angiogenesis inhibitors in breast cancers, there may be an indication for it in the triple negative breast cancers. As bevacizumab is used in glioblastoma multiforme, there may be a need for it in CD44 high, CD24 low, and ALDH1 high expressing tumors which have high CNS affinity.

Conclusion

As the molecular analyses shed more light on triple negative breast cancer, we think it will become the norm to do these analyses on this unique type of cancer. This will be the major molecular determinant to lead to the individualization of care for this cancer.

Disclosure

The author reports no conflicts of interest in this work.

References
